Advertisement

Tumor Biology

, Volume 37, Issue 5, pp 6107–6116 | Cite as

Anti-tumor angiogenesis effect of a new compound: B-9-3 through interference with VEGFR2 signaling

  • Qin Ma
  • Wei Chen
  • Wen Chen
Original Article

Abstract

B-9-3, a derivative of harmine, was first synthesized in our laboratory. We have reported that B-9-3 has an anti-proliferative effect against human lung cancer cells via induction of apoptosis and inhibition of cell migration. In the present study, we first studied that the anti-tumor angiogenesis effect and the molecular mechanism of B-9-3-induced tumor vascular degrade and mortify in lung cancer. In vitro, the results showed that B-9-3 selectively inhibited the proliferation of endothelial cells IC50 = 6.16 μg/ml) and vascular fibroblasts (IC50 = 12.59 μg/ml) and induced regression of tumor cells of the following: Lewis lung carcinoma (LLC), Mouse fore-stomach carcinoma (MFC), Human ovarian cancer (SK-OV-3), and prostate cancer (22RV1). Moreover, B-9-3 could significantly increase the apoptosis rate (80.95 %) of vascular endothelial cells, while inhibiting migration of endothelial cells, capillary tube formation of endothelial cells, neovascularization of the rat thoracic aorta ring, and the angiogenesis of chick chorioallantoic membrane (CAM) predominantly through blocking VEGFR2 signaling pathway. In vivo, we investigated the anti-tumor rate and the signal transduction mechanism of B-9-3 by LCC-bearing C57BL/6 mice. The data showed that the tumor inhibition ratio of high dose (20 mg/kg) of B-9-3 was 72.9 %, and quantification of CD34 marker indicated a marked reduction in the number of neovessels after B-9-3 treatment as compared with control group (66.87 %). Remarkably, using IHC and q-RT-PCR, we found that downregulation of the expression of VEGFR2, VEGF-A, and TGFβ1 in tumor confers enhancement to the angiogenesis effect of B-9-3. These data suggest that the angiogenesis inhibitor B-9-3 selectively induces apoptosis of endothelial cells, in part through disruption of VEGF-A/VEGFR2 signaling.

Keywords

B-9-3 Harmine Angiogenesis inhibitor VEGFR2 Lung caner 

Notes

Acknowledgments

This work was supported by grants from the China SME Technology Innovation Fund of Xinjiang Production and Construction Corp (No. 2015AE009)

Compliance with ethical standards

Conflicts of interest

None

References

  1. 1.
    Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249.CrossRefPubMedGoogle Scholar
  2. 2.
    Cabebe E, Wakelee H. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options in Oncol. 2007;8:15.CrossRefGoogle Scholar
  3. 3.
    Zhu Z, Hattori K, Zhang H, Jimenez X, Ludwig DL, Dias S, et al. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia. 2003;17:604.CrossRefPubMedGoogle Scholar
  4. 4.
    Doyle B, Caplice N. Plaque neovascularization and antiangiogenic therapy for atherosclerosis. J Am Coll Cardiol. 2007;49:2073.CrossRefPubMedGoogle Scholar
  5. 5.
    Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391.CrossRefPubMedGoogle Scholar
  6. 6.
    Ling Y, Lu N, Gao Y, Chen Y, Wang S, Yang Y, et al. Endostar induces apoptotic effects in HUVECs through activation of caspase-3 and decrease of Bcl-2. Anticancer Res. 2009;29:411.PubMedGoogle Scholar
  7. 7.
    Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335.CrossRefPubMedGoogle Scholar
  8. 8.
    Kramer I, Lipp HP. Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. J Clin Pharm Ther. 2007;32:1.CrossRefPubMedGoogle Scholar
  9. 9.
    Wells Jr SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30:134.CrossRefGoogle Scholar
  10. 10.
    Grosios K, Holwell SE, McGown AT, Pettit GR, Bibby MC. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer. 1999;81:1318.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Ferrari G, Pintucci G, Seghezzi G, Hyman K, Galloway AC, Mignatti P. VEGF, a prosurvival factor, acts in concert with TGF-beta1 to induce endothelial cell apoptosis. Proc Natl Acad Sci U S A. 2006;103:17260.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Ferrari G, Cook BD, Terushkin V, Pintucci G, Mignatti P. Transforming growth factor-beta 1 (TGF-beta1) induces angiogenesis through vascular endothelial growth factor (VEGF)-mediated apoptosis. J Cell Physiol. 2009;219:449.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Kim KY, Lee JW, Ahn BW, Ryu PD, Nam MJ. Loss of endogenous TGF-beta effect induces mouse hepatoma malignancy by correlation with cyclooxygenase-2 and VEGF. Hepatol Res. 2003;26:302.CrossRefPubMedGoogle Scholar
  14. 14.
    Malik AK, Baldwin ME, Peale F, Fuh G, Liang WC, Lowman H, et al. Redundant roles of VEGF-B and PlGF during selective VEGF-A blockade in mice. Blood. 2006;107:550.CrossRefPubMedGoogle Scholar
  15. 15.
    Pollman MJ, Naumovski L, Gibbons GH. Vascular cell apoptosis: cell type-specific modulation by transforming growth factor-beta1 in endothelial cells versus smooth muscle cells. Circulation. 1999;99:2019.CrossRefPubMedGoogle Scholar
  16. 16.
    Moloudizargari M, Mikaili P, Aghajanshakeri S, Asghari MH, Shayegh J. Pharmacological and therapeutic effects of Peganum harmala and its main alkaloids. Pharmacogn Rev. 2013;7:199.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    S Breza T Jr, Magro CM. Lichenoid and granulomatous dermatitis associated with atypical mycobacterium infections. J Cutan Pathol. 2006;33:512.Google Scholar
  18. 18.
    Herraiz T, Gonzalez D, Ancin-Azpilicueta C, Aran VJ, Guillen H. beta-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO). Food Chem Toxicol. 2010;48:839.CrossRefPubMedGoogle Scholar
  19. 19.
    Zhong Z, Tao Y, Yang H. Treatment with harmine ameliorates functional impairment and neuronal death following traumatic brain injury. Mol Med Rep. 2015.Google Scholar
  20. 20.
    Song Y, Wang J, Teng SF, Kesuma D, Deng Y, Duan J, et al. Beta-carbolines as specific inhibitors of cyclin-dependent kinases. Bioorg Med Chem Lett. 2002;12:1129.CrossRefPubMedGoogle Scholar
  21. 21.
    Han X, Zhang J, Guo L, Cao R, Li Y, Li N, et al. A series of beta-carboline derivatives inhibit the kinase activity of PLKs. PLoS One. 2012;7:e46546.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Beyer J, Drummer OH, Maurer HH. Analysis of toxic alkaloids in body samples. Forensic Sci Int. 2009;185:1.CrossRefPubMedGoogle Scholar
  23. 23.
    Cao R, Peng W, Chen H, Ma Y, Liu X, Hou X, et al. DNA binding properties of 9-substituted harmine derivatives. Biochem Biophys Res Commun. 2005;338:1557.CrossRefPubMedGoogle Scholar
  24. 24.
    Piekarski M, Dolhan A, Cielecka-Piontek J, Zalewski P, Kycler W, Kaczmarek A, et al. The influence of pH and temperature on the stability of N-[(piperidine)methylene]daunorubicin hydrochloride and a comparison of the stability of daunorubicin and its four new amidine derivatives in aqueous solutions. Sci World J. 2014;2014:803789.CrossRefGoogle Scholar
  25. 25.
    Phalen DN, Frimberger A, Pyecroft S, Peck S, Harmsen C, Lola S, et al. Vincristine chemotherapy trials and pharmacokinetics in tasmanian devils with tasmanian devil facial tumor disease. PLoS One. 2013;8:e65133.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Daoud A, Song J, Xiao F, Shang J. B-9-3, a novel beta-carboline derivative exhibits anti-cancer activity via induction of apoptosis and inhibition of cell migration in vitro. Eur J Pharmacol. 2014;724:219.CrossRefPubMedGoogle Scholar
  27. 27.
    Mousa SA, O’Connor LJ, Bergh JJ, Davis FB, Scanlan TS, Davis PJ. The proangiogenic action of thyroid hormone analogue GC-1 is initiated at an integrin. J Cardiovasc Pharmacol. 2005;46:356.CrossRefPubMedGoogle Scholar
  28. 28.
    Adhami VM, Malik A, Zaman N, Sarfaraz S, Siddiqui IA, Syed DN, et al. Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin Cancer Res. 2007;13:1611.CrossRefPubMedGoogle Scholar
  29. 29.
    Tuxhorn JA, McAlhany SJ, Dang TD, Ayala GE, Rowley DR. Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. Cancer Res. 2002;62:3298.PubMedGoogle Scholar
  30. 30.
    Yuan JS, Reed A, Chen F, Stewart Jr CN. Statistical analysis of real-time PCR data. BMC Bioinf. 2006;7:85.CrossRefGoogle Scholar
  31. 31.
    Hamsa TP, Kuttan G. Harmine inhibits tumour specific neo-vessel formation by regulating VEGF, MMP, TIMP and pro-inflammatory mediators both in vivo and in vitro. Eur J Pharmacol. 2010;649:64.CrossRefPubMedGoogle Scholar
  32. 32.
    Frost D, Meechoovet B, Wang T, Gately S, Giorgetti M, Shcherbakova I, et al. beta-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer’s disease-related sites. PLoS One. 2011;6:e19264.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438:967.CrossRefPubMedGoogle Scholar
  34. 34.
    Liss AS, Thayer SP. Therapeutic targeting of pancreatic stroma. In: Grippo PJ, Munshi HG, editors. Pancreatic cancer and tumor microenvironment. Trivandrum (India). 2012.Google Scholar
  35. 35.
    Oguro Y, Miyamoto N, Okada K, Takagi T, Iwata H, Awazu Y, et al. Design, synthesis, and evaluation of 5-methyl-4-phenoxy-5H-pyrrolo[3,2-d]pyrimidine derivatives: novel VEGFR2 kinase inhibitors binding to inactive kinase conformation. Bioorg Med Chem. 2010;18:7260.CrossRefPubMedGoogle Scholar
  36. 36.
    Zhang J, Li Y, Guo L, Cao R, Zhao P, Jiang W, et al. DH166, a beta-carboline derivative, inhibits the kinase activity of PLK1. Cancer Biol Ther. 2009;8:2374.CrossRefPubMedGoogle Scholar
  37. 37.
    Pollman MJ, Naumovski L, Gibbons GH. Endothelial cell apoptosis in capillary network remodeling. J Cell Physiol. 1999;178:359.CrossRefPubMedGoogle Scholar
  38. 38.
    Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis. 2014;17:471.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Sidney LE, Branch MJ, Dunphy SE, Dua HS, Hopkinson A. Concise review: evidence for CD34 as a common marker for diverse progenitors. Stem Cells. 2014;32:1380.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Xinjiang Huashidan Drug-Discovery Co., Ltd.UrumchiChina
  2. 2.College of PharmacyShihezi UniversityShiheziChina

Personalised recommendations